About: Plasma biomarker screening for liver fibrosis with the N-terminal isotope tagging strategy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Plasma biomarker screening for liver fibrosis with the N-terminal isotope tagging strategy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Plasma biomarker screening for liver fibrosis with the N-terminal isotope tagging strategy
Creator	Lai, Wei Liu, Xin Jiang, Ying Handong, Wei He Fuchu, Huifen, Wang Li, Shulong Xiaohong, Qian Zhang, Jiyang
Source	Medline; PMC
abstract	A non-invasive diagnostic approach is crucial for the evaluation of severity of liver disease, treatment decisions, and assessing drug efficacy. This study evaluated plasma proteomic profiling via an N-terminal isotope tagging strategy coupled with liquid chromatography/Fourier transform ion cyclotron resonance mass spectrometry measurement to detect liver fibrosis staging. Pooled plasma from different liver fibrosis stages, which were assessed in advance by the current gold-standard of liver biopsy, was quantitatively analyzed. A total of 72 plasma proteins were found to be dysregulated during the fibrogenesis process, and this finding constituted a valuable candidate plasma biomarker bank for follow-up analysis. Validation results of fibronectin by Western blotting reconfirmed the mass-based data. Ingenuity Pathways Analysis showed four types of metabolic networks for the functional effect of liver fibrosis disease in chronic hepatitis B patients. Consequently, quantitative proteomics via the N-terminal acetyl isotope labeling technique provides an effective and useful tool for screening plasma candidate biomarkers for liver fibrosis. We quantitatively monitored the fibrogenesis process in CHB patients. We discovered many new valuable candidate biomarkers for the diagnosis of liver fibrosis and also partly identified the mechanism involved in liver fibrosis disease. These results provide a clearer understanding of liver fibrosis pathophysiology and will also hopefully lead to improvement of clinical diagnosis and treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available for this article at 10.1007/s11427-011-4165-y and is accessible for authorized users.
has issue date	2011-05-15(xsd:dateTime)
bibo:doi	10.1007/s11427-011-4165-y
bibo:pmid	21574042
has license	cc-by-nc
sha1sum (hex)	4c3f357d50bfeede5dd0eec81a4b5b7f116c628a
schema:url	https://doi.org/10.1007/s11427-011-4165-y
resource representing a document's title	Plasma biomarker screening for liver fibrosis with the N-terminal isotope tagging strategy
has PubMed Central identifier	PMC7088802
has PubMed identifier	21574042
schema:publication	Sci China Life Sci
resource representing a document's body	covid:4c3f357d50bfeede5dd0eec81a4b5b7f116c628a#body_text
is schema:about of	named entity 'proteomic' named entity 'fibrosis' named entity 'proteomics' named entity 'plasma' named entity 'plasma' named entity 'proteins' named entity 'fibrosis' named entity 'total' named entity 'These' named entity 'drug' named entity 'N-terminal' covid:arg/4c3f357d50bfeede5dd0eec81a4b5b7f116c628a named entity 'mass-based' named entity 'proteomics' named entity 'N-terminal' named entity 'plasma' named entity 'candidate' named entity 'candidate' named entity 'cyclotron' named entity 'ion' named entity 'fibrosis' named entity 'evaluated' named entity 'liquid chromatography' named entity 'tagging' named entity 'screening' named entity 'clinical diagnosis' named entity 'biomarkers' named entity 'biomarker' named entity 'liver fibrosis' named entity 'liver fibrosis' named entity 'proteomic' named entity 'fibronectin' named entity 'fibrogenesis' named entity 'plasma' named entity 'metabolic networks' named entity 'liver fibrosis' named entity 'plasma proteins' named entity 'N-terminal' named entity 'Citation' named entity 'infection' named entity 'hepatocellular carcinoma' named entity 'autoimmune diseases' named entity 'peptide' named entity 'fibrosis' named entity 'protein' named entity 'free light chains' named entity 'Serpin' named entity 'antinuclear antibody' named entity 'peptides' named entity 'tumor' named entity 'post-translational modifications' named entity 'glycoprotein' named entity 'neurological disease' named entity 'MS/MS' named entity 'liver fibrosis' named entity 'proteomic' named entity 'CHB' named entity 'm/z' named entity 'hemoglobin' named entity 'mass spectrometry' named entity 'up-regulated' named entity 'liver' named entity 'liver fibrosis' named entity 'hepatitis' named entity 'biochemical' named entity 'exact test' named entity 'peptide' named entity 'peptide' named entity 'Clusterin' named entity 'immunological' named entity 'staining' named entity 'supernatant' named entity 'ion'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software